|
Q1 2024
|
112 |
5,757,958 |
CERE, FOLD, IOVA, ACLX
|
13F-HR
|
5/15/2024 |
000101297524000218 |
|
Q4 2023
|
101 |
4,479,991 |
CERE, FOLD, LIAN, ACLX
|
RESTATEMENT
|
2/26/2024 |
000101297524000112 |
|
Q3 2023
|
97 |
2,997,910 |
FOLD, CERE, IMVT, ACLX
|
13F-HR
|
11/14/2023 |
000101297523000471 |
|
Q2 2023
|
95 |
3,454,832 |
FOLD, CERE, LIAN, ACLX
|
RESTATEMENT
|
8/24/2023 |
000101297523000365 |
|
Q1 2023
|
99 |
3,387,005 |
FOLD, RETA, AMLX, CERE
|
RESTATEMENT
|
5/16/2023 |
000101297523000242 |
|
Q4 2022
|
96 |
3,561,179 |
FOLD, AMLX, MDGL, CERE
|
13F-HR
|
2/14/2023 |
000101297523000099 |
|
Q3 2022
|
116 |
3,445,660 |
FOLD, MRTX, CERE, GLOBAL BLOOD THERAPEUTICS IN
|
13F-HR
|
11/14/2022 |
000101297522000502 |
|
Q2 2022
|
111 |
3,192,812 |
TRAVERE THERAPEUTICS INC, FOLD, MRTX, CERE
|
13F-HR
|
8/15/2022 |
000101297522000365 |
|
Q1 2022
|
135 |
4,992,282 |
TRAVERE THERAPEUTICS INC, FOLD, SWTX, LIAN
|
13F-HR
|
5/16/2022 |
000101297522000241 |
|
Q4 2021
|
147 |
6,488,711 |
TRAVERE THERAPEUTICS INC, MRTX, LIAN, FOLD
|
NEW HOLDINGS
|
5/4/2022 |
000101297522000209 |
|
Q4 2021
|
145 |
6,477,012 |
TRAVERE THERAPEUTICS INC, MRTX, LIAN, FOLD
|
RESTATEMENT
|
4/13/2022 |
000101297522000160 |
|
Q3 2021
|
140 |
6,884,438 |
MRTX, TRAVERE THERAPEUTICS INC, BBIO, SWTX
|
RESTATEMENT
|
12/3/2021 |
000101297521000492 |
|
Q2 2021
|
150 |
7,706,312 |
MRTX, BBIO, SWTX, RETROPHIN INC
|
NEW HOLDINGS
|
8/17/2021 |
000101297521000326 |
|
Q2 2021
|
149 |
7,690,907 |
MRTX, BBIO, SWTX, RETROPHIN INC
|
13F-HR
|
8/16/2021 |
000101297521000320 |
|
Q1 2021
|
139 |
7,907,737 |
MRTX, BBIO, RETROPHIN INC, SWTX
|
RESTATEMENT
|
8/13/2021 |
000101297521000299 |
|
Q1 2021
|
139 |
7,928,028 |
MRTX, BBIO, RETROPHIN INC, SWTX
|
NEW HOLDINGS
|
6/10/2021 |
000101297521000242 |
|
Q4 2020
|
139 |
9,318,287 |
MRTX, FOLD, BBIO, RETROPHIN INC
|
13F-HR
|
2/16/2021 |
000101297521000086 |
|
Q3 2020
|
126 |
6,849,575 |
MRTX, RETROPHIN INC, FOLD, IOVA
|
13F-HR
|
11/16/2020 |
000101297520000835 |
|
Q2 2020
|
125 |
6,171,121 |
FOLD, GLOBAL BLOOD THERAPEUTICS IN, RETROPHIN INC, IOVA
|
RESTATEMENT
|
8/17/2020 |
000101297520000701 |
|
Q1 2020
|
113 |
3,839,552 |
IOVA, GLOBAL BLOOD THERAPEUTICS INC, NBIX, MRTX
|
RESTATEMENT
|
5/18/2020 |
000101297520000472 |
|
Q4 2019
|
114 |
5,034,133 |
GLOBAL BLOOD THERAPEUTICS INC, MRTX, NBIX, KOD
|
RESTATEMENT
|
2/19/2020 |
000101297520000250 |
|
Q3 2019
|
109 |
3,711,799 |
NBIX, GLOBAL BLOOD THERAPEUTICS INC, MRTX, IOVA
|
13F-HR
|
11/14/2019 |
000101297519000707 |
|
Q2 2019
|
104 |
4,358,000 |
NBIX, GLOBAL BLOOD THERAPEUTICS INC, MRTX, IOVA
|
13F-HR
|
8/14/2019 |
000101297519000583 |
|
Q1 2019
|
105 |
3,544,255 |
NBIX, FOLD, GLOBAL BLOOD THERAPEUTICS INC, ZGNX
|
RESTATEMENT
|
5/16/2019 |
000101297519000380 |
|
Q4 2018
|
101 |
2,627,578 |
NBIX, GLOBAL BLOOD THERAPEUTICS IN, FOLD, ZGNX
|
13F-HR
|
2/14/2019 |
000101297519000177 |
|
Q3 2018
|
117 |
3,739,830 |
NBIX, FOLD, GLOBAL BLOOD THERAPEUTICS IN, ZGNX
|
13F-HR
|
11/14/2018 |
000101297518001239 |
|
Q2 2018
|
125 |
3,814,393 |
NBIX, FOLD, GLOBAL BLOOD THERAPEUTICS IN, ALNY
|
RESTATEMENT
|
11/1/2018 |
000101297518001190 |
|
Q1 2018
|
137 |
3,570,243 |
NBIX, FOLD, GLOBAL BLOOD THERAPEUTICS IN, ZGNX
|
13F-HR
|
5/15/2018 |
000101297518000425 |
|
Q4 2017
|
132 |
3,016,759 |
NBIX, FOLD, GLOBAL BLOOD THERAPEUTICS IN, ALNY
|
13F-HR
|
2/14/2018 |
000101297518000171 |
|
Q3 2017
|
139 |
2,617,539 |
NBIX, FOLD, ALNY, GLOBAL BLOOD THERAPEUTICS IN
|
RESTATEMENT
|
11/14/2017 |
000101297517000846 |
|
Q2 2017
|
126 |
1,987,272 |
FOLD, NBIX, ALNY, GLOBAL BLOOD THERAPEUTICS IN
|
13F-HR
|
8/14/2017 |
000101297517000624 |
|
Q1 2017
|
173 |
1,755,479 |
NBIX, GLOBAL BLOOD THERAPEUTICS SHARES, FOLD, ARAV
|
13F-HR
|
5/15/2017 |
000101905617000467 |
|
Q4 2016
|
198 |
1,406,244 |
NBIX, TSRO, FOLD, SRPT
|
RESTATEMENT
|
5/2/2017 |
000101905617000406 |
|
Q3 2016
|
196 |
1,549,231 |
SRPT, NBIX, FOLD, TSRO
|
13F-HR
|
11/14/2016 |
000101905616001648 |
|
Q2 2016
|
173 |
1,442,487 |
SRPT puts, NBIX, TSRO, FOLD
|
13F-HR
|
8/11/2016 |
000101905616001477 |
|
Q1 2016
|
170 |
1,140,104 |
FOLD, NBIX, SRPT, TSRO
|
13F-HR
|
5/16/2016 |
000101905616001336 |
|
Q4 2015
|
155 |
1,351,627 |
FOLD, NBIX, SRPT, DYAX
|
13F-HR
|
2/16/2016 |
000101905616001109 |
|
Q3 2015
|
158 |
1,252,059 |
FOLD, NBIX, SRPT, TVTX
|
NEW HOLDINGS
|
11/17/2015 |
000101905615000911 |
|
Q3 2015
|
158 |
1,250,856 |
FOLD, NBIX, SRPT, TVTX
|
13F-HR
|
11/16/2015 |
000101905615000908 |
|
Q2 2015
|
173 |
1,660,639 |
FOLD, NBIX, TVTX, SRPT
|
13F-HR
|
8/14/2015 |
000101905615000685 |
|
Q1 2015
|
158 |
1,286,807 |
FOLD, NBIX, TVTX, TSRO
|
13F-HR
|
5/15/2015 |
000101905615000506 |
|
Q4 2014
|
150 |
1,192,435 |
FOLD, NBIX, ACELRX PHARMACEUTICALS INC, SRPT
|
13F-HR
|
2/17/2015 |
000101905615000222 |
|
Q3 2014
|
125 |
988,010 |
FOLD, NBIX, AFMD, SRPT
|
RESTATEMENT
|
11/17/2014 |
000101905614001426 |
|
Q2 2014
|
117 |
1,019,307 |
SRPT, NBIX, ACELRX PHARMACEUTICALS INC, VRTX
|
13F-HR
|
8/14/2014 |
000101905614001053 |
|
Q1 2014
|
127 |
951,682 |
ACELRX PHARMACEUTICALS INC, NBIX, SRPT, VRTX
|
13F-HR
|
5/15/2014 |
000101905614000699 |
|
Q4 2013
|
110 |
832,601 |
CELG, ACELRX PHARMACEUTICALS INC, SRPT, VRTX
|
13F-HR
|
2/14/2014 |
000101905614000254 |